As informações fornecidas no EL7.AI são apenas para fins educacionais e informativos e não constituem aconselhamento financeiro.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

AçõesMédio•30 March 2026•

1 min de leitura

Revelation Biosciences Reports Positive Clinical Data for Gemini in CKD Patients

Fatos Principais

1Revelation Biosciences presented additional data from the PRIME study showing Gemini's ability to normalize cellular inflammation.

2Results demonstrated restoration of immunocompetence for up to 7 days after a single dose in chronic kidney disease (CKD) patients.

3The data was presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026).

Cadastre-se grátis para acessar este conteúdo

Criar Conta Gratuita

Revelation Biosciences Inc. (NASDAQ: REVB) has released additional clinical data from its PRIME study evaluating the drug candidate Gemini. The latest findings demonstrate Gemini's ability to normalize cellular inflammation and restore immunocompetence in patients with stage 3 and 4 chronic kidney disease (CKD). Presented at the AKI & CRRT 2026 conference, the data showed that a single dose could sustain immune restoration for up to 7 days. The company aims to highlight Gemini's therapeutic potential in treating hyperinflammatory states and addressing immunoparalysis. This announcement marks a significant milestone for the clinical-stage biotech firm as it advances its specialized pipeline. Market analysts view these results as a bullish catalyst for REVB shares, reflecting progress in addressing critical unmet medical needs in nephrology.